OTC · INTI
Inhibitor Therapeutics, Inc.
$0.07$0.00 (0.0%)
Inhibitor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
Loading market information…
OTC · OPGN · USD
Stock price, earnings
Quote as of Mar 19, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
OpGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow OpGen, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OpGen, Inc. is a precision medicine company dedicated to developing and commercializing advanced molecular microbiology solutions for both U.S. and international markets. Its comprehensive product suite includes the Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test designed to pinpoint various bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR) from bacterial colonies sourced from diverse specimen types. The company also offers Curetis CE-IVD-marked polymerase chain reaction (PCR)-based test kits for SARS-CoV-2 detection. Beyond diagnostics, OpGen provides sophisticated platforms like the ARES Technology Platform. This platform features the ARES reference database, which leverages next-generation sequencing technology and artificial intelligence-powered bioinformatics to predict antibiotic response for antimicrobial resistance. Another core offering is the Unyvero Platform, an automated, sample-to-answer molecular diagnostics system. It seamlessly integrates automated sample preparation, analysis, and identification of disease-relevant pathogens and their associated antibiotic resistance markers. Fundamentally, OpGen harnesses molecular diagnostics and informatics to actively combat infectious diseases. The company empowers clinicians by providing crucial insights into life-threatening infections, thereby enhancing patient outcomes and significantly slowing the spread of infections caused by multidrug-resistant microorganisms. In a notable collaboration, OpGen is partnered with the New York State Department of Health and ILÚM Health Solutions, LLC, to establish a research program. This initiative focuses on the detection, tracking, and effective management of antimicrobial-resistant infections within healthcare institutions. Established in 2001, OpGen, Inc. maintains its corporate headquarters in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$4.60-6.98% vs estimate |
| $699.02K+9.22% vs estimate |
| Q2 2023 | Aug 10, 2023 | -$9.30-30.99% vs estimate | $736.14K-18.21% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.07$0.00 (0.0%)
Inhibitor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.58% below the high.
£0.63£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 76.79% below the high.
£1.46£0.00 (0.0%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 61.59% below the high.
$0.04$0.00 (0.0%)
LianMedical’s quoted price sits in the lower half of its reported 52-week range, 75.14% below the high.
$0.00$0.00 (0.0%)
Univec, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.22% below the high.
$0.01$0.00 (0.0%)
Nass Valley Gateway Ltd.: Healthcare · Medical - Distribution.
$0.01$0.00 (0.0%)
NuGen Medical Devices Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.3% below the high.
$0.15$0.00 (0.0%)
Blum Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
